PolyPeptide Group AG shareholders approved all proposals at an extraordinary general meeting, electing a new board of directors and removing longstanding transfer and voting restrictions, moves that will take effect only if Samsung Biologics' public tender offer is settled. The decisions, announced via NEWMEDIAWIRE, signal a decisive shift in control for the specialized peptide CDMO and could reshape its strategic direction.
Shareholders elected John Chongbo Rim, Seungho Ryu, Cheol Woo Ryu, Mihyun Yang and Joonkyung Seong to the board for terms ending at the next annual general meeting. Rim was elected chair, while Cheol Woo Ryu and Seungho Ryu join the Remuneration and Nomination Committee. These appointments are contingent on the settlement of the tender offer by Samsung Peptide AG, a wholly owned subsidiary of Samsung Biologics Co., Ltd., for all publicly held registered shares of PolyPeptide.
Shareholders also resolved to remove the transfer restrictions (Vinkulierung) and voting limitations (Stimmrechtsbeschränkungen) from PolyPeptide's articles of association, subject to the satisfaction or waiver of all offer conditions outlined in the August 31, 2026 offer prospectus, except for one specific condition. The removal of these restrictions is significant because it eliminates key barriers to a full takeover, allowing Samsung Biologics to acquire shares without the previous caps and transfer hurdles that could have deterred the offer.
The board overhaul and the elimination of transfer restrictions are directly tied to the Samsung Biologics tender offer, meaning they will only become effective upon settlement. This conditionality underscores the high stakes of the transaction for PolyPeptide, a company with a global network of six GMP-certified facilities and a portfolio heavily exposed to metabolic diseases, including GLP-1 therapies. A change of control could influence its customer relationships, manufacturing priorities, and growth trajectory in the rapidly expanding peptide market.
For investors, the approval of these proposals reduces uncertainty around the takeover process, as the new board and removed restrictions are prerequisites for Samsung Biologics to finalize its acquisition. The development also highlights the strategic value Samsung Biologics places on PolyPeptide's peptide manufacturing capabilities, which are increasingly in demand for next-generation therapies.
Detailed results of the meeting are available in the PolyPeptide_EGM Results 2026_ENG document, and the original release can be viewed on www.newmediawire.com. PolyPeptide's shares are listed on SIX Swiss Exchange under the ticker PPGN, and further information about the company is available at polypeptide.com.
